The intranasal Covid vaccine from Bharat Biotech was licenced for limited emergency usage on Tuesday by the Drugs Controller General of India (DCGI).

India's Battle Against COVID-19 Gets a Huge Boost! The @CDSCO INDIA INF has approved Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine for primary COVID-19.

COVID-19 immunisation in the 18+ age group for only limited usage in emergency situations "Mansukh Mandaviya, the union's minister of health, tweeted.

Under the direction of PM, he claimed, India has leveraged its scientific, research and development (R&D), and human resources in the struggle against COVID-19.

We will beat COVID-19 with the science-driven strategy and Sabka Prayas in upcoming days effectively, added Mandaviya.

According to corporate insiders, Hyderabad-based Bharat Biotech International Limited (BBIL) has finished the nasal vaccine's clinical testing.

Clinical testing with roughly 4,000 participants, and so far there have been no side effects or adverse reactions observed.

It claimed in August that COVID-19 intranasal vaccine (BBV154) patients in controlled clinical trials phase -3 had shown the vaccine to be secure, well-tolerated, and immunogenic.

The nasal delivery system has also been created and engineered to be affordable in low- and middle-income nations, according to the vaccine manufacturer.

 These might offer a chance to lessen infection and transmission. Additional research is being considered, "the business claimed.

Additionally, the DCGI authorised the company to carry out a phase 3 clinical trial to evaluate the immunogenicity and safety of BBV154 (intranasal) vs Covaxin.